BioCentury | Mar 25, 2021
Management Tracks

Galapagos promotes Filius to president, Litchfield named Merck CFO; plus moves at LianBio, Adverum, Fulcrum, Aptose, Cyclerion, Medigene, Apie and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Bart Filius to president from CFO while remaining COO. CEO Onno van de Stolpe will be responsible for oversight of R&D activities. Caroline Litchfield will succeed Robert Davis as CFO of Merck...
BioCentury | Feb 13, 2021
Finance

Qiming readies to kick off Chinese New Year with a first for Hong Kong exchange

After Qiming closed its sixth RMB fund in late January, Managing Partner Nisa Leung is looking ahead to her firm’s second public listing this year, one that she believes could clear a path for...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...
BioCentury | Oct 27, 2020
Distillery Therapeutics

ZDHHC7 and LYPLA2 identified as targets in Crohn’s, ulcerative colitis

DISEASE CATEGORY: Autoimmune disease INDICATION: Inflammatory bowel disease (IBD); Crohn’s disease Inhibiting ZDHHC7 and LYPLA2 — two genes that regulate membrane localization of the...
BioCentury | Jul 16, 2020
Politics, Policy & Law

Intelligence agencies warn of cyber espionage against COVID-19 R&D

Hackers working for Russian intelligence services are targeting COVID-19 vaccine R&D in the U.S., Canada and the U.K., according to a report released Thursday by the U.K.’s National Cyber Security Centre and Canada’s Communications Security...
BioCentury | Jun 20, 2020
Product Development

China offers forward-thinking biotechs much more than an opportunity to get delayed clinical trials back on track

Weiji (危机), the Chinese term for crisis, combines the characters for “danger” and “opportunity,” an apt description of the challenge posed by COVID-19. While most of the world struggles with pandemic containment and ‘re-opening,’ China,...
BioCentury | Apr 4, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

New Therapeutic Targets and Biomarkers: March 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Mar 14, 2019
Clinical News

Adare’s APT-1011 meets in Phase IIb for eosinophilic esophagitis

Adare said it plans to start a Phase III program next half of APT-1011 (AdvaTab Fluticasone) to treat eosinophilic esophagitis after reporting that the product met the primary endpoint in the Phase IIb FLUTE trial...
BioCentury | Mar 5, 2019
Distillery Therapeutics

MC1R, ZDHHC13 and LYPLA2 as new targets for melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Mouse studies suggest activating MC1R by expressing ZDHHC13 or inhibiting LYPLA2 could help treat melanoma. In a mouse model of melanoma, transgenic expression of human ZDHHC13, which palmitoylates MC1R to...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest inhibiting IL-1β alone or in combination with PD-1 could help treat breast cancer. In a mouse model of breast cancer, IL-1β knockdown or an anti-IL-1β antibody decreased tumor growth...
Items per page:
1 - 10 of 81